Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study

BackgroundDostarlimab is a humanized monoclonal antibody that binds with high affinity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2. We report interim data from patients with endometrial cancer (EC) participating in a phase I trial of single-agent dostarlimab.MethodsGARNET, an ongo...

Full description

Saved in:

Bibliographic Details
Published in:	Journal for immunotherapy of cancer Vol. 10; no. 1; p. e003777
Main Authors:	Oaknin, Ana, Gilbert, Lucy, Tinker, Anna V, Brown, Jubilee, Mathews, Cara, Press, Joshua, Sabatier, Renaud, O’Malley, David M, Samouelian, Vanessa, Boni, Valentina, Duska, Linda, Ghamande, Sharad, Ghatage, Prafull, Kristeleit, Rebecca, Leath III, Charles, Guo, Wei, Im, Ellie, Zildjian, Sybil, Han, Xinwei, Duan, Tao, Veneris, Jennifer, Pothuri, Bhavana
Format:	Journal Article
Language:	English
Published:	England BMJ Publishing Group Ltd 01.01.2022 BMJ Publishing Group LTD BMJ Publishing Group
Series:	Original research
Subjects:	Antibodies, Monoclonal, Humanized - pharmacology Antibodies, Monoclonal, Humanized - therapeutic use Biomarkers Biomarkers, Tumor - metabolism Cancer Cell death clinical trials as topic Clinical/Translational Cancer Immunotherapy DNA Mismatch Repair - drug effects Endometrial cancer Endometrial Neoplasms - drug therapy Enrollments Female Humans Hypotheses Immunotherapy Laboratories Life Sciences Microsatellite Instability - drug effects Middle Aged Monoclonal antibodies Mutation Patients programmed cell death 1 receptor Proteins Response rates Targeted cancer therapy Tumors clinical trials as topic programmed cell death 1 receptor immunotherapy
ISSN:	2051-1426, 2051-1426
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!